RxDoctor Payments Data

Benjamin Scoll, MD

Urology · Portland, MENPI 1174762116

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $566 of the $784 with a category attached, or 72.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 16.6%. Reporting peaked in 2023 at $221 and has fallen 67.5% since, to $72 in 2025. That places this record below the midpoint for urology clinicians in ME, where the typical reported total is $1,024.

$784in general payments, 2019–2025

Across 29 payments — averaging $27.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$130
  • Boston Scientific$104
  • Progenics Pharmaceuticals, Inc.$91
  • Pfizer$85
  • Dentsply IH Inc.$82
  • Janssen Scientific Affairs, LLC$72
  • plus $220 from 7 others

What the payments were for

  • Food & beverage$56672%
  • Education$21828%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$784 in reported general payments places this provider in the 40th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$129,275
Medicare patients
267
Services billed
5,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide15$217,917
OrgovyxRelugolix31$82,620
MyrbetriqMirabegron47$32,323
Testosterone55$7,447
Tamsulosin Hcl617$6,995
Tolterodine Tartrate ErTolterodine Tartrate89$6,067
Solifenacin Succinate84$4,592
Trospium Chloride31$2,858
Potassium Citrate ErPotassium Citrate17$2,551
Finasteride143$1,816
Oxybutynin Chloride ErOxybutynin Chloride60$1,325
Alfuzosin Hcl ErAlfuzosin Hcl45$1,029
Tadalafil20$968
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav54$789
Testosterone Cypionate16$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$130$217,91715 claims
Sumitomo Pharma America, Inc.Orgovyx$26$82,62031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 59 urology providers in Maine.

Other urology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →